(Q37088536)

18 August 2017

1 reference

title

PET/CT in the management of haematological malignancies (English)

1 reference

18 August 2017

1

Martin Hutchings

1 reference

18 August 2017

2

Lena Specht

1 reference

18 August 2017

language of work or name

1 reference

12 February 2008

1 reference

European Journal of Haematology

18 August 2017

published in

1 reference

18 August 2017

volume

80

1 reference

18 August 2017

issue

5

1 reference

18 August 2017

page(s)

369-380

1 reference

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Follicular lymphoma international prognostic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Cross-sectional imaging with CT and/or MRI of pediatric chest tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Positron emission tomography for the staging of Hodgkin's lymphoma--increasing the body of evidence in favor of the method

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography-clinical use, interpretation methods, diagnostic improvements

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Positron emission tomography in patients with primary CNS lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

The value of positron emission tomography/computed tomography (PET/CT) in the staging of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Utility of FDG-PET scanning in lymphoma by WHO classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Assessment of response to therapy using conventional imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Early therapy monitoring with FDG-PET in aggressive non-Hodgkin?s lymphoma and Hodgkin?s lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose c

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Is there any future in radiotherapy planning without the use of PET: unraveling the myth...

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

The role of PET/CT scanning in radiotherapy planning

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Positron emission tomography in pediatric radiation oncology: integration in the treatment-planning process

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

PET and PET/CT for response evaluation in lymphoma: current practice and developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

FDG-PET/CT in re-staging of patients with lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Quantitative CT analysis for assessing response in lymphoma (Cheson's criteria).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

PET and restaging of malignant lymphoma including residual masses and relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Hodgkin lymphoma: Response assessment by revised International Workshop Criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: a randomized study caveat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Initial results in the assessment of multiple myeloma using 18F-FDG PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Diagnostic utility of FDG PET in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Positron emission tomography (PET) for staging of solitary plasmacytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Value of FDG PET in the assessment of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Guidelines for the use of imaging in the management of myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

PET/CT and MR imaging in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

Diffuse bone marrow accumulation of FDG in a patient with chronic myeloid leukemia mimics hematopoietic cytokine-mediated FDG uptake on positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01051.X

10.1111/J.1600-0609.2008.01051.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference